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Introduction
Millions of individuals worldwide are exposed 
to inorganic arsenic through drinking water 
as well as dietary sources (Smith et al. 2000). 
Arsenic is a well-established human carcino gen 
(International Agency for Research on Cancer 
2012); however, the exact mechanism by 
which it causes cancer has not been established 
(Kitchin and Conolly 2010). There is in vitro 
and in vivo evidence to suggest that epi genetic 
alterations may mediate arsenic toxicity, 
as recently reviewed by Reichard and Puga 
(2010) and Ren et al. (2011).
Several human studies have examined 
global DNA methylation in blood in relation 
to arsenic exposure using surrogate markers 
of global DNA methylation, such as long 
interspersed nucleotide element-1 (LINE-1), 
Alu element methylation, methyl incorpo-
ration assays, or luminometric methyla tion 
assays. The findings from those studies have 
largely been inconsistent and included a 
number of differences in exposure measures 
and doses across studies (Hossain et al. 2012; 
Intarasunanont et al. 2012; Kile et al. 2012; 
Lambrou et al. 2012; Majumdar et al. 2010; 
Pilsner et al. 2007, 2009, 2012; Tajuddin 
et al. 2013; Wilhelm et al. 2010). Several 
other studies have evaluated arsenic in relation 
to gene-specific DNA methylation, most 
frequently assessing p16 and p53 promoter 
methylation (Chanda et al. 2006; Chen et al. 
2007; Engström et al. 2013; Hossain et al. 
2012; Intarasunanont et al. 2012; Marsit et al. 
2006; Zhang et al. 2007). However, rela-
tively few epigenome-wide DNA methyla tion 
studies have been conducted to investigate 
epi genetic alterations of arsenic toxicity in 
humans, evaluating associations with arsenical 
skin lesion status (Seow et al. 2014; Smeester 
et al. 2011), urinary arsenic species (Bailey 
et al. 2013), in utero arsenic exposure (Kile 
et al. 2014; Koestler et al. 2013a), toenail 
arsenic concentration (Liu et al. 2014), or 
arsenic-related uro thelial carcinomas (Yang 
et al. 2014). Smeester et al. (2011) examined 
epigenome-wide promoter DNA methyla-
tion in peripheral blood leukocytes among 
16 arsenic-exposed females from Mexico in 
relation to skin lesion status, and observed 
183 differentially methylated genes, of 
which 182 were hyper methylated. Bailey 
et al. (2013) evaluated the data of Smeester 
et al. (2011) in relation to urinary arsenic 
species and observed nominally significant 
differential promoter DNA methylation in 
812 unique genes, of which the majority 
were hypo methylated compared with relative 
urinary arsenic metabo lite species. Koestler 
et al. (2013a) evaluated in utero arsenic 
exposure in relation to epigenome-wide 
cord blood methyla tion in 134 U.S.-based 
individuals and observed evidence of enrich-
ment of hyper methylated loci in CpG 
islands, as well as a suggested indication of 
endocrine-disrupting effects of arsenic 
through hypo methylation of ESR1 (estrogen 
receptor 1) and PPARGC1A (peroxisome 
proliferator-activated receptor gamma, 
coactivator 1 alpha). 
The evidence noted above warrants further 
investigation of arsenic exposure on gene-
specific DNA methylation in a comprehen-
sive manner, and in a larger study population 
to identify potential mechanisms associated 
with arsenic-related toxicity. We conducted 
an epigenome-wide association study among 
400 Bangladeshi individuals with manifest 
arsenical skin lesions to assess whether arsenic 
exposure level (as measured by blood arsenic 
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Background: Inorganic arsenic is one of the most common naturally occurring contaminants 
found in the environment. Arsenic is associated with a number of health outcomes, with epigenetic 
modification suggested as a potential mechanism of toxicity.
oBjective: Among a sample of 400 adult participants, we evaluated the association between arsenic 
exposure, as measured by blood and urinary total arsenic concentrations, and epigenome-wide 
white blood cell DNA methylation.
Methods: We used linear regression models to examine the associations between arsenic exposure 
and methylation at each CpG site, adjusted for sex, age, and batch. Differentially methylated loci 
were subsequently examined in relation to corresponding gene expression for functional evidence of 
gene regulation.
results: In adjusted analyses, we observed four differentially methylated CpG sites with 
urinary total arsenic concentration and three differentially methylated CpG sites with blood 
arsenic concentration, based on the Bonferroni-corrected significance threshold of p < 1 × 10–7. 
Methylation of PLA2G2C (probe cg04605617) was the most significantly associated locus in 
relation to both urinary (p = 3.40 × 10–11) and blood arsenic concentrations (p = 1.48 × 10–11). 
Three additional novel methylation loci—SQSTM1 (cg01225779), SLC4A4 (cg06121226), and 
IGH (cg13651690)—were also significantly associated with arsenic exposure. Further, there was 
evidence of methylation-related gene regulation based on gene expression for a subset of differentially 
methylated loci.
conclusions: We observed significant associations between arsenic exposure and gene-specific 
differential white blood cell DNA methylation, suggesting that epi genetic modifications may be an 
important pathway under lying arsenic toxicity. The specific differentially methylated loci identified 
may inform potential pathways for future interventions.
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and urinary total arsenic concentrations) is 
associated with differential white blood cell 
DNA methylation.
Methods
Study population. The Bangladesh Vitamin E 
and Selenium Trial is a 2 × 2 factorial random-
ized chemoprevention trial evaluating the 
long-term effects of vitamin E and selenium 
supplementation on non melanoma skin 
cancer risk (Argos et al. 2013). Participants 
were residents of rural communities in central 
Bangladesh. Eligibility criteria included age 
between 25 and 65 years, permanent resi-
dence in the study area, manifest arsenical 
skin lesions, and no prior cancer history. 
Between April 2006 and August 2009, a total 
of 7,000 individuals were enrolled into the 
study. Trained study physicians, blinded to 
participants’ arsenic exposure, conducted 
in-person interviews and clinical evalua-
tions, and collected urine and blood samples 
from participants in their homes using struc-
tured protocols. Of participants enrolled in 
the study, 413 were randomly sampled 
for epigenome-wide methylation analyses; 
baseline biological specimens collected before 
the start of the trial intervention were used in 
the analyses. 
The study protocol was approved by the 
relevant institutional review boards in the 
United States (The University of Chicago 
and Columbia University) and Bangladesh 
(Bangladesh Medical Research Council). 
Informed consent was provided by partici-
pants prior to the baseline interview of the 
original study.
Exposure assessment. Urinary total 
arsenic concentration was measured in the 
baseline spot urine sample by graphite 
furnace atomic absorption spectrometry 
(AAnalyst 600 spectrometer; PerkinElmer, 
Norwalk, CT, USA) with a detection limit 
of 2 μg/L, in a single laboratory (Trace Metal 
Core Laboratory at Columbia University) 
(Nixon et al. 1991). Urinary creatinine was 
also measured for all participants in the 
same laboratory by a colorimetric method 
based on the Jaffe reaction (Heinegård and 
Tiderström 1973). Urinary total arsenic was 
divided by creatinine to obtain a creatinine-
adjusted urinary total arsenic concentration, 
expressed as micrograms per gram creatinine. 
Creatinine-adjusted urinary total arsenic, 
a good biomarker of aggregate ingested 
arsenic exposure, captures exposure from all 
sources including water, food, soil, and dust 
(Hughes 2006).
Venous whole blood samples collected 
at baseline were analyzed for blood arsenic 
concentration by inductively coupled 
plasma mass spectrometry (ICP-MS) 
using a PerkinElmer Elan DRC (dynamic 
reaction cell) II equipped with an AS 93+ 
auto sampler (PerkinElmer). ICP-MS-DRC 
methods for metals in whole blood were 
developed according to published procedures 
(Pruszkowski et al. 1998; Stroh 1988), with 
modifications for blood sample preparation 
as suggested by the Laboratory for ICP-MS 
Comparison Program (Institut National de 
Sante Publique du Québec).
DNA methylation. DNA was extracted 
using DNeasy Blood kits (Qiagen, Valencia, 
CA, USA), and bisulfite conversion was 
performed using the EZ DNA Methylation 
Kit (Zymo Research, Irvine, CA, USA). 
DNA methylation was measured in 500 ng of 
bisulfite-converted DNA per sample using the 
Illumina HumanMethylation 450K BeadChip 
kit (Illumina, San Diego, CA, USA) according 
to the manufacturer’s protocol; this beadchip 
allows interro gation of 485,577 CpG sites 
per sample. The methylation score for each 
CpG site, represented as the β value, on a 
continuous scale between 0 (unmethylated) 
and 1 (completely methylated) was quantile 
normalized. Among the 413 participants for 
whom DNA methyla tion data were generated, 
we excluded 6 samples for which the reported 
sex of the participant did not correspond with 
predicted sex based on methyla tion patterns 
of the X and Y chromosomes, and 7 samples 
with > 5% of CpGs either containing missing 
values or having p for detection > 0.05. This 
resulted in 400 samples retained for analyses. 
We omitted individual β values that were 
associated with a p for detection > 0.05. We 
also excluded probes on the X (n = 11,232) 
and Y (n = 416) chromosomes, probes with 
missing chromosome data (mostly control 
probes; n = 65), and probes with > 10% 
missing data across samples (n = 1,932); this 
resulted in a total of 471,932 probes included 
in the statistical analyses. Quantile-normalized 
β values were logit transformed and adjusted 
for batch variability using ComBat software 
(Johnson et al. 2007). Based on 11 samples 
run in duplicate across two different plates 
in these experiments, the average inter assay 
Spearman correlation coefficient (rs) was 
0.987 (range, 0.974–0.993).
Gene expression. Mono nuclear cells were 
preserved in Buffer RLT and stored at –80°C; 
RNA was then extracted using the RNeasy 
Micro Kit from QIAGEN (Valencia, CA, 
USA). The concentration and quality of RNA 
was checked on a Nanodrop 1000 spectro-
photometer (Thermo Scientific, Wilmington, 
DE, USA). cRNA synthesis was performed 
using 250 ng of RNA using the Illumina 
TotalPrep 96 RNA Amplification kit. Gene 
expression was measured using the Illumina 
HumanHT-12-v4 BeadChip utilizing 750 ng 
of cRNA according to the manufacturer’s 
protocol. The chip contains a total of 47,231 
probes covering 31,335 genes. Quantile-
normalized expression values were log2 
transformed and adjusted for batch variability 
using ComBat software (Johnson et al. 2007). 
Gene expression data were available for the 
400 individuals included in these analyses.
Genotyping. Genotyping procedures have 
been described in detail previously (Pierce et al. 
2012). Briefly, DNA extraction was carried 
out from whole blood using the QIAamp 96 
DNA Blood Kit (QIAGEN, Valencia, CA, 
USA). Any DNA sample with a concentration 
< 40 ng/μL, a 260 nm/280 nm ratio outside 
the range of < 1.6 to ≥ 2.1 (measured by 
Nanodrop 1000), or fragmented DNA < 2 kb 
(assessed by smearing in Agilent BioAnalyzer) 
was excluded. Genotyping was performed 
using the Illumina HumanCytoSNP-12 
BeadChip utilizing 250 ng DNA according 
to the manufacturer’s protocol. Using 
257,768 genotyped single nucleo tide poly-
morphisms (SNPs) after quality control proce-
dures, we performed imputation using MaCH 
on the basis of the HapMap 3 Gujarati Indians 
in Houston (GIH) population (Build 36; 
http://hapmap.ncbi.nlm.nih.gov/downloads/
phasing/2009-02_phaseIII/HapMap3_r2/), 
yielding 1,211,988 SNPs after quality control 
procedures. Genotype data were available for 
393 individuals included in these analyses.
Replication study. For replication of 
our top differentially methylated loci, we 
examined associations in an independent 
sample of 48 Bangladeshi adult males from 
the ongoing Folate and Creatinine Trial 
(FACT), prior to intervention. No partici-
pants in this sample had manifest arsenical 
skin lesions. The methods used to measure 
and analyze DNA methylation have been 
described in detail by Harper et al. (2013). 
Briefly, the water arsenic concentration 
was measured for all study participants at 
Columbia University, as previously described 
(Van Geen et al. 2002), and individuals were 
Table 1. Selected characteristics of the study 
sample.



















Values are n (%) unless otherwise noted.
aMean ± SD. 
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categorized as having low (50–100 μg/L, 
n = 25) or high (> 100 μg/L, n = 23) 
exposure for statistical analyses. After Ficoll 
separation, DNA from peripheral blood 
mononuclear cells (PBMCs) was extracted 
using the 5 PRIME ArchivePure DNA Blood 
Kit (Fisher Scientific, Pittsburgh, PA, USA). 
Epigenome-wide methylation of PBMC 
DNA was measured at the Roswell Park 
Cancer Institute (Buffalo, NY, USA) using the 
Illumina HumanMethylation 450K BeadChip 
kit. Data were processed using a standard 
quality control protocol and adjusted for 
batch effects prior to analyses using ComBat 
(Johnson et al. 2007). Here, we report 
associations from linear regression models. 
Statistical analyses. For each CpG site, 
a separate linear regression model was run 
regressing the logit-transformed β value 
on continuous arsenic exposure (i.e., blood 
arsenic or urinary total arsenic concentration), 
sex, and age. Here, we present model coef-
ficients and SEs from the linear regression 
models comparing the 75th versus the 25th 
percentile of each arsenic distribution. To 
correct for multiple comparisons, we consid-
ered a Bonferroni-corrected (p < 1 × 10–7) 
significance threshold; however, we present 
results for all loci with p < 1 × 10–5. For differ-
entially methylated probes with p < 1 × 10–5, 
we used linear regression to examine the 
associa tion of methylat ion with corresponding 
RNA transcript levels of the gene containing 
the methyla tion locus, adjusted for sex, age, 
and urinary total arsenic concentration. 
Methylation and expression data were 
adjusted for batch effects prior to analyses 
using ComBat (Johnson et al. 2007). 
ComBat batch-adjusted methyla tion 
data were used to infer white blood cell 
type fractions using the statistical method 
of Houseman et al. (2012). Briefly, we used 
466 methyla tion probes previously identified 
to be associated with leukocyte distributions 
(Houseman et al. 2012) to infer the distribu-
tion of white blood cell types in our study 
samples. Linear regression was used to evaluate 
the association between quartiles of arsenic 
exposure, based on the distribution in our 
study sample, in relation to the estimated cell 
type fractions adjusted for sex and age.
To evaluate previously reported associa-
tions from other studies, we conducted a 
lookup of individual CpG loci of interest 
within our data set. For these analyses a CpG 
locus associated with p < 0.05 was considered 
to be statistically significant. We used the R 
program MethLAB v1.5 (Kilaru et al. 2012) 
and SAS software (SAS Institute Inc., Cary, 
NC, USA) to run all analyses.
Results
Characteristics of the study sample are 
summarized in Table 1. We ran models 
separately for blood and urinary total arsenic 
concentrations (rs = 0.91). We identified 
three loci that were significantly differen-
tially methylated in relation to blood arsenic 
concentration based on the Bonferroni 
threshold p < 1 × 10–7, as shown in Figure 1. 
We identified four loci that were significantly 
differentially methylated in relation to urinary 
total arsenic concentration based on the 
Bonferroni threshold p < 1 × 10–7, as shown 
in Figure 2. The loci based on the Bonferroni 
threshold were common between the two 
analyses, and several overlapping associa-
tions that did not meet the strict Bonferroni 
threshold but that had p < 1 × 10–5 were also 
observed between the exposure analyses, as 
summarized in Table 2. Furthermore, there 
appeared to be enrichment for differen-
tially methylated loci in relation to urinary 
and blood arsenic concentrations in ocean 
(isolated CpG loci in the genome) and 
CpG island shore regions (within 2 kb from 
a CpG island; see Supplemental Material, 
Figure S1). Only a single gene contained 
more than one differentially methylated 
locus with p < 1 × 10–5; hyper methylation 
of cg04605617 (chr1: 20,501,558) and 
cg08042135 (chr1: 20,501,758) in PLA2G2C 
was observed (rs = 0.53). However, after 
adjustment of cg08042135 by cg04605617, 
the associations with blood (p = 0.14) and 
urinary total arsenic (p = 0.24) no longer 
persisted. Sensitivity analyses conducted 
with arsenic exposure as a natural log-
transformed variable did not appreciably 
alter the association p-values (data not 
shown), suggesting robust linear associations 
for reported loci. In addition, the methyla-
tion β values are presented by urinary total 
arsenic exposure quartiles in Supplemental 
Material, Figure S2. In general, we observed 
dose- dependent trends between urinary total 
arsenic quartiles and DNA methyla tion levels. 
Box plots looked similar for blood arsenic 
quartiles (data not shown).
Among all 471,932 CpG loci evaluated, 
56.6% of the methylation probes were hyper-
methylated (t-statistic > 0) and 43.4% were 
hypo methylated (t-statistic < 0) in relation to 
urinary total arsenic concentration. Results 
Figure 1. Manhattan plot for epigenome-wide association results for blood 
arsenic concentration. The horizontal red line corresponds to the significance 
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Figure 2. Manhattan plot for epigenome-wide association results for urinary total 
arsenic concentration. The horizontal red line corresponds to the significance 
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were similar in relation to blood arsenic 
concentration (data not shown). Among 
the top 35 differen tially methylated loci, 
blood and urinary total arsenic levels were 
associated with both gene-specific DNA 
hyper methylation (n = 19; 54.3%) and gene-
specific DNA hypo methylation (n = 16; 
45.7%), as shown in Table 2 (p = 0.78 for 
enrichment). Furthermore, no statistically 
significant association of arsenic exposure was 
observed in relation to global methyla tion 
levels across auto somes on a genomic scale. 
In a global analysis evaluating the association 
between arsenic exposure and average β values 
across all available CpG sites, we observed 
no significant global methyla tion patterns 
for blood (p = 0.124) or urinary total arsenic 
(p = 0.241) concentrations.
Among the 35 differentially methylated 
loci with p < 1 × 10–5, 29 loci could be 
evaluated in the replication sample. Of these, 
8 methyla tion loci were associated with 
p < 0.05, with 5 loci observed to have the same 
direction of effect as the discovery associa tion 
(see Supplemental Material, Table S1). The 
strongest replication signal was observed for 
IGH (cg13651690; p = 5.40 × 10–3). The 
Kolmogorov test indicated that the replica-
tion p-values were significantly different from a 
uniform p-value distribution (p = 0.0011).
Methylation probes containing known 
SNPs were not removed from analyses 
a priori because genome-wide SNP data were 
available for the study sample (Pierce et al. 
2012) and could be examined in stratified 
analyses. As shown in Table 2, among the 
significantly differentially methylated loci 
based on Bonferroni criteria, one probe 
contained a SNP with minor allele frequency 
≥ 0.01. Methylation probe cg04605617 
contained SNP rs12139100 for which 
genotype data were available on 363 of the 
400 study participants. The A allele frequency 
in the study sample was 0.38. In stratified 
analyses, the association between blood 
and urinary total arsenic concentrations in 
relation to DNA methyla tion at cg04605617 
was observed to be independent of the 
rs12139100 genotype. Among individuals 
with the GG genotype (n = 136), associations 
persisted in relation to DNA methyla tion for 
blood arsenic concentration (p = 3.08 × 10–4) 
and urinary total arsenic concentration 
(p = 6.20 × 10–5), as well as among individ-
uals with the GA+AA genotype (n = 227) for 
blood arsenic concentration (p = 1.61 × 10–7) 
and urinary total arsenic concentration 
(p = 2.43 × 10–7).
We examined the correlation between 
white blood cell DNA methyla tion with 
corresponding PBMC gene expression for 
the top 35 differentially methylated probes 
among the 400 study participants. Gene 
expression signals based on RNA transcripts 
for the corresponding genes containing the 
differentially methylated loci are summa-
rized in Table 3. Among the 35 differentially 
methylated loci with p < 1 × 10–5, we could 
evaluate corresponding RNA transcript levels 
from the same gene for 28 methyla tion loci. 
Of these, 15 methyla tion loci were signifi-
cantly associated with gene expression based 
on p < 0.1.
To evaluate the potential effect of 
arsenic exposure on white blood cell type 
Table 2. Top 35 differentially methylated loci based on p < 1 × 10–5 in relation to blood or urinary total arsenic concentrations, sorted by chromosome (Chr).
CpG Chr Position Gene Feature categorya
Median 
β value
Blood arsenic  
concentration
Urinary total arsenic  
concentration
Coefficient SE p-Value Coefficient SE p-Value
cg02856716 1  18,993,307 PAX7 Body 0.102 –0.014 0.004 2.28 × 10–4 –0.019 0.004 6.46 × 10–6
cg04605617b 1  20,501,558 PLA2G2C 1st exon 0.724 0.049 0.007 1.48 × 10–11* 0.054 0.008 3.40 × 10–11*
cg08042135 1  20,501,758 PLA2G2C TSS200 0.774 0.019 0.004 2.71 × 10–6 0.020 0.004 1.37 × 10–5
cg13223043 1  26,492,308 FAM110D||ZNF593 Intergenic 0.448 –0.021 0.004 1.48 × 10–6 –0.022 0.005 6.78 × 10–6
cg00857921 1  92,257,380 TGFBR3 Body 0.393 0.016 0.004 4.12 × 10–5 0.021 0.004 1.98 × 10–6
cg19750321 1  150,808,974 ARNT Body 0.853 0.017 0.004 7.06 × 10–6 0.016 0.004 2.20 × 10–4
cg03984502 1  151,805,662 RORC TSS1500 0.816 0.020 0.004 6.44 × 10–6 0.015 0.005 2.34 × 10–3
cg07207669 1  155,102,389 EFNA1 Body 0.560 –0.023 0.005 5.90 × 10–7 –0.025 0.005 1.27 × 10–6
cg08438392 2  27,708,645 IFT172 Body 0.782 0.020 0.004 3.27 × 10–6 0.022 0.005 3.66 × 10–6
cg00522451 2  113,464,049 SLC20A1||NT5DC4 Intergenic 0.216 –0.025 0.005 2.49 × 10–7 –0.028 0.005 3.16 × 10–7
cg00281776c 2  209,224,226 PIKFYVE||PTH2R Intergenic 0.817 –0.038 0.008 1.22 × 10–6 –0.042 0.009 1.50 × 10–6
cg25881170 3  107,810,508 CD47 TSS1500 0.473 0.019 0.004 3.28 × 10–6 0.022 0.005 1.14 × 10–6
cg24262469 3  156,391,694 TIPARP-AS1 Body 0.371 0.022 0.005 8.48 × 10–6 0.022 0.005 4.98 × 10–5
cg06121226 4  72,134,061 SLC4A4 Body 0.463 –0.054 0.009 7.63 × 10–9* –0.059 0.010 1.16 × 10–8*
cg01225779 5  179,238,473 SQSTM1 5’ UTR 0.562 –0.042 0.007 6.00 × 10–9* –0.048 0.008 2.37 × 10–9*
cg19937878 6  13,296,150 TBC1D7 Body 0.820 0.028 0.007 1.91 × 10–5 0.035 0.007 1.59 × 10–6
cg11230112d 6  158,460,980 SYNJ2 Body 0.872 –0.029 0.006 6.60 × 10–7 –0.029 0.007 1.54 × 10–5
cg22813794 7  75,677,469 MDH2 TSS200; 5’ UTR 0.039 –0.059 0.014 5.49 × 10–5 –0.077 0.016 1.54 × 10–6
cg15310871 8  20,077,937 ATP6V1B2 3’ UTR 0.825 –0.039 0.008 3.61 × 10–7 –0.042 0.008 1.09 × 10–6
cg22977892 8  25,907,769 PPP2R2A Body 0.254 0.021 0.005 7.70 × 10–6 0.020 0.005 1.20 × 10–4
cg02268561 10  15,212,066 NMT2 TSS1500 0.118 –0.026 0.005 6.23 × 10–7 –0.026 0.006 7.74 × 10–6
cg15108641 10  99,263,321 UBTD1 Body 0.365 0.033 0.006 3.70 × 10–7 0.030 0.007 3.11 × 10–5
cg07545081 10  126,308,381 FAM53B 3’ UTR 0.685 0.021 0.005 3.42 × 10–6 0.026 0.005 3.68 × 10–7
cg02742555 11  15,200,693 INSC Body 0.163 –0.028 0.005 2.22 × 10–7 –0.026 0.006 2.74 × 10–5
cg03348792 12  53,075,482 KRT1 TSS1500 0.309 0.019 0.004 6.62 × 10–6 0.019 0.005 8.91 × 10–5
cg06383241 12  116,997,023 MAP1LC3B2 TSS200 0.083 –0.022 0.005 2.29 × 10–6 –0.022 0.005 2.23 × 10–5
cg11582226 13  77,587,297 FBXL3 Body 0.756 0.021 0.004 3.40 × 10–6 0.019 0.005 1.98 × 10–4
cg13651690 14  106,320,748 IGH Body 0.950 0.035 0.006 1.24 × 10–7 0.039 0.007 9.16 × 10–8*
cg05018460 15  80,688,079 AB240015||ARNT2 Intergenic 0.557 0.047 0.010 1.56 × 10–6 0.046 0.011 2.09 × 10–5
cg04352288e 16  87,958,408 CA5A Body 0.872 0.047 0.011 9.20 × 10–6 0.056 0.012 2.60 × 10–6
cg17892169 17  7,452,644 TNFSF12-TNFSF13 Body 0.341 0.024 0.005 8.06 × 10–6 0.023 0.006 2.01 × 10–4
cg08285388 17  27,230,177 DHRS13 TSS200 0.090 –0.014 0.004 1.37 × 10–3 –0.022 0.005 3.29 × 10–6
cg13480898 19  10,195,915 C19orf66 TSS1500 0.680 –0.023 0.005 5.35 × 10–6 –0.026 0.005 1.63 × 10–6
cg06381803 19  46,119,476 EML2 Body 0.400 –0.042 0.010 5.72 × 10–5 –0.051 0.011 8.95 × 10–6
cg26390598 21  41,032,397 B3GALT5 5’ UTR 0.340 0.050 0.011 9.03 × 10–6 0.063 0.012 5.49 × 10–7
Abbreviations: TSS, transcription start site; TSS200, 200 bases from TSS; TSS1500, 1,500 bases from TSS; UTR, untranslated region. “||” indicates an intergenic region. Four probes 
contain SNPs with a minor allele frequency ≥ 0.01. All SNPs > 10 bases from query site.
aGene feature category of the methylation locus. brs12139100. crs139141387. drs73795212. ers113904153. *p < 1 × 10–7.
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proportions, we utilized estimated cell type 
fractions based on a validated subset of the 
methyla tion data, presented by quartiles of 
arsenic exposure in Table 4. We observed no 
notable effect of arsenic on cell type propor-
tions, except for moderate estimated percent 
decreases in CD4+ T cells and natural killer 
(NK) cells in relation to the highest quartile 
of urinary total arsenic concentration as well 
as borderline associations (p = 0.13–0.14) 
in relation to the highest quartile of blood 
arsenic concentration.
Discussion
The findings of this study suggest associations 
of blood and urinary total arsenic concentra-
tions with gene-specific DNA methyla tion 
changes. We identified four novel methyla-
tion loci in PLA2G2C, SQSTM1, SLC4A4, 
and IGH that were strongly associated with 
arsenic exposure (p < 1 × 10–7), as well as 
several suggestive associations in other gene 
regions. In addition, we observed that several 
of the differentially methylated loci were asso-
ciated with corresponding gene expression 
levels in PBMCs.
Higher arsenic exposure was associ-
ated with increased methyla tion levels at 
cg04605617 (chr1: 20,501,558), located in 
the first exon of PLA2G2C. This locus was 
Table 3. Top 35 differentially methylated loci based on p < 1 × 10–5 in relation to peripheral blood mononuclear cell (PMBC) gene expression, sorted by 
chromosome (Chr).
CpG Chr Position Gene Feature categorya Expression probe Probe coordinates p-Value Direction 
cg02856716 1 18,993,307 PAX7 Body ILMN_1835658 19,074,941–19,074,990 0.574 +
ILMN_1761061 19,062,405–19,062,454 0.818 +
cg04605617 1 20,501,558 PLA2G2C 1st Exon ILMN_3237030 20,501,573–20,501,622 0.073 +
ILMN_1656867 20,490,548–20,490,597 0.324 –
cg08042135 1 20,501,758 PLA2G2C TSS200 ILMN_1656867 20,490,548–20,490,597 0.742 –
ILMN_3237030 20,501,573–20,501,622 0.758 +
cg13223043 1 26,492,308 FAM110D||ZNF593 Intergenic NA
cg00857921 1 92,257,380 TGFBR3 Body ILMN_1784287 92,148,163–92,148,212 1.620 × 10–8 –
cg19750321 1 150,808,974 ARNT Body ILMN_1762582 150,782,288–150,782,337 0.351 +
ILMN_2347314 150,782,989–150,783,038 0.552 –
cg03984502 1 151,805,662 RORC TSS1500 ILMN_1771126 151,778,991–151,779,040 3.001 × 10–6 –
ILMN_1734366 151,778,901–151,778,950 4.770 × 10–6 –
ILMN_1651792 151,804,215–151,804,264 0.247 +
ILMN_2275399 151,798,406–151,798,455 0.992 –
cg07207669 1 155,102,389 EFNA1 Body ILMN_2371055 155,107,215–155,107,264 0.140 +
ILMN_2371053 155,106,804–155,106,853 0.272 –
cg08438392 2 27,708,645 IFT172 Body ILMN_1784178 27,668,277–27,668,621 0.428 –
cg00522451 2 113,464,049 SLC20A1||NT5DC4 Intergenic NA
cg00281776 2 209,224,226 PIKFYVE||PTH2R Intergenic NA
cg25881170 3 107,810,508 CD47 TSS1500 ILMN_2356991 107,762,694–107,762,743 0.044 +
ILMN_1771333 107,762,387–107,762,436 0.060 +
cg24262469 3 156,391,694 TIPARP-AS1 Body ILMN_3239662 157,875,849–157,875,878 0.223 +
cg06121226 4 72,134,061 SLC4A4 Body ILMN_1734897 72,437,058–72,437,107 2.173 × 10–4 +
ILMN_2184556 72,437,334–72,437,383 0.029 +
cg01225779 5 179,238,473 SQSTM1 5’ UTR NA
cg19937878 6 13,296,150 TBC1D7 Body ILMN_1661622 13,305,354–13,305,403 0.567 –
cg11230112 6 158,460,980 SYNJ2 Body ILMN_2215119 158,438,833–158,438,882 0.752 +
cg22813794 7 75,677,469 MDH2 TSS200; 5’ UTR ILMN_2079004 75,695,852–75,695,901 0.867 +
cg15310871 8 20,077,937 ATP6V1B2 3’ UTR ILMN_1787705 20,078,945–20,078,994 0.004 –
cg22977892 8 25,907,769 PPP2R2A Body NA
cg02268561 10 15,212,066 NMT2 TSS1500 ILMN_2062620 15,147,945–15,147,994 0.030 +
cg15108641 10 99,263,321 UBTD1 Body ILMN_1794914 99,330,592–99,330,641 2.416 × 10–6 –
cg07545081 10 126,308,381 FAM53B 3’ UTR ILMN_2053490 126,308,101–126,308,150 0.280 –
ILMN_1704571 126,308,260–126,308,309 0.834 –
cg02742555 11 15,200,693 INSC Body ILMN_1756070 15,262,019–15,262,068 0.343 +
ILMN_2340643 15,267,549–15,267,598 0.983 +
cg03348792 12 53,075,482 KRT1 TSS1500 ILMN_1735712 53,068,865–53,068,914 0.298 +
cg06383241 12 116,997,023 MAP1LC3B2 TSS200 ILMN_3247613 115,481,580–115,481,621 0.005 –
cg11582226 13 77,587,297 FBXL3 Body ILMN_2071405 77,579,718–77,579,767 0.299 +
cg13651690 14 106,320,748 IGH Body NA
cg05018460 15 80,688,079 AB240015||ARNT2 Intergenic NA
cg04352288 16 87,958,408 CA5A Body ILMN_1731292 87,921,734–87,921,783 0.004 +
cg17892169 17 7,452,644 TNFSF12-TNFSF13 Body ILMN_1683700 7,460,967–7,461,016 0.022 –
ILMN_2399190 7,462,480–7,462,529 0.031 +
ILMN_1784264 7,464,109–7,464,339 0.150 +
ILMN_1670188 7,452,806–7,453,453 0.335 –
ILMN_1680003 7,457,089–7,457,138 0.819 +
cg08285388 17 27,230,177 DHRS13 TSS200 ILMN_1790781 27,224,816–27,224,865 0.366 –
cg13480898 19 10,195,915 C19orf66 TSS1500 ILMN_1750400 10,203,832–10,203,881 0.004 +
cg06381803 19 46,119,476 EML2 Body ILMN_3240541 50,804,842–50,804,886 0.028 –
cg26390598 21 41,032,397 B3GALT5 5’ UTR ILMN_1698756 39,954,012–39,954,061 0.059 –
ILMN_2378654 39,956,034–39,956,083 0.206 –
ILMN_1800713 39,956,436–39,956,485 0.376 –
Abbreviations: –, inverse association between methylation and gene expression levels; +, positive association between methylation and gene expression levels; NA, not available; 
TSS, transcription start site; TSS200, 200 bases from TSS; TSS1500, 1,500 bases from TSS; UTR, untranslated region. “||” indicates an intergenic region. 
aGene feature category of the methylation locus.
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moderately associated with increased gene 
expression of PLA2G2C (ILMN_3237030, 
p = 0.073). PLA2G2C encodes a calcium-
dependent phospho lipase, which is an enzyme 
involved in the hydrolysis of phospholipids 
into free fatty acids and lyso phospho lipids. 
These lipid mediators have diverse biological 
functions relevant for cancer progression, 
including roles in inflammation and cell 
growth, signaling, and death (Dennis et al. 
2011; Scott et al. 2010). Notably, phospho-
lipase A2 enzymes have been shown to be 
induced by skin carcinogens (e.g., phorbol 
ester, ultraviolet B light), which ultimately 
leads to prostaglandin synthesis via cyclo-
oxygenase-2 (COX2) leading to increased 
keratino cyte proliferation and skin carcino-
genesis (Bowden 2004; Kast et al. 1993). 
Arsenic is an established skin carcinogen, with 
evidence from animal studies suggesting over-
expression of COX2 associated with arsenic 
exposure (Ouyang et al. 2007; Tokar et al. 
2011; Trouba and Germolec 2004).
Higher arsenic exposure was associated 
with decreased methyla tion levels at the 
cg01225779 locus (chr5: 179,238,473), 
located in the 5´ untranslated region (UTR) 
of SQSTM1. SQSTM1 encodes a protein that 
binds ubiquitin and regulates activation of 
the nuclear factor kappa-B (NF-κB) signaling 
pathway. SQSTM1 has been implicated in 
a number of diseases including neuro-
degenerative diseases, cancer, obesity, and 
insulin resistance (Geetha et al. 2012). In vitro 
studies have shown that arsenic induces the 
NF-κB pathway and may be a potential 
mecha nism for skin carcinogenesis (Liao et al. 
2004; Zuo et al. 2012).
Higher arsenic exposure was associated 
with decreased methyla tion levels at the 
cg06121226 locus (chr4: 72,134,061). 
This locus, located in the body of SLC4A4, 
was strongly associated with increased gene 
expression of SLC4A4 (ILMN_2356991, 
p = 2.173 × 10–4 and ILMN_2184556, 
p = 0.029). SLC4A4 encodes a sodium 
bicarbonate cotransporter involved in the 
regulation of bicarbonate secretion and 
absorption, as well as intra cellular pH. 
Mutations in this gene have been asso-
ciated with hyper tension (Yang et al. 
2012), a well-established health outcome 
associated with arsenic exposure (Abhyankar 
et al. 2012).
Higher arsenic exposure was also 
associated with increased methyla tion levels at 
the cg13651690 locus (chr14: 106,320,748), 
located in the body of IGH. The immuno-
globulin heavy locus includes variable (V), 
diversity (D), joining (J), and constant (C) 
segments of immunoglobulins. Translocations 
in this region have been implicated in 
lymphoma (Guais et al. 2004). Arsenic 
exposure has been associated with elevated 
serum immuno globulins (Islam et al. 2007), 
which may be involved in skin carcino genesis 
(Wiemels et al. 2011). Furthermore, we 
observed significant replication of this locus 
in an independent study sample in relation to 
water arsenic concentration. 
The biological implications of these 
findings must be further explored with regard 
to their role in various mechanisms of arsenic 
toxicity and arsenic-related disease outcomes. 
Chronic exposure to arsenic in drinking 
water has been associated with a multitude 
of health effects, including increased risks 
of cancer, cardio vascular disease, peripheral 
neuropathy, and respiratory diseases (Brouwer 
et al. 1992; Chen et al. 1992; Milton and 
Rahman 2002; Navas-Acien et al. 2005), as 
well as a possible association with diabetes 
(Argos et al. 2013; Navas-Acien et al. 2006). 
Future studies should be designed to evaluate 
phenotype-specific methyla tion patterns in 
arsenic-exposed populations. In addition, 
we found that the magnitude of differential 
methyla tion at each locus associated with 
arsenic exposure was small, although similar 
in size to estimated effects previously reported 
for arsenic and other environmental exposures 
(Joubert et al. 2012; Koestler et al. 2013a). 
The biological implications of relatively small 
changes in DNA methyla tion need to be 
elucidated further.
Among the seven epigenome-wide studies 
regarding arsenic-related traits published 
to date (Bailey et al. 2013; Kile et al. 2014; 
Koestler et al. 2013a; Liu et al. 2014; Seow 
et al. 2014; Smeester et al. 2011; Yang et al. 
2014), only two of the studies did not use the 
Illumina platform for measurement of DNA 
methyla tion (Bailey et al. 2013; Smeester 
et al. 2011). In the present study, we observed 
no overlap between our top 35 differentially 
methylated loci and the top signals previously 
reported for other arsenic-related traits among 
studies that used the Illumina methyla tion 
array, although none of these prior studies 
identified statistically differentially methyl-
ated loci based on a Bonferroni threshold 
(p < 1 × 10–7). We also conducted a lookup of 
the top reported CpG signals from the previ-
ously published studies in our data set (see 
Supplemental Material, Table S2). Nominally 
significant associations in our data set 
have previously been reported for AGAP2 
cg11511175 and RHBDF1 cg03333116 
in relation to arsenical skin lesion status 
(Seow et al. 2014); ELL cg22489759 and 
SNRNP200 cg00088989 in relation to toenail 
arsenic concentration (Liu et al. 2014); and 
RIN2 cg03512414, SLC12A6 cg11293029, 
CBFA2T3 cg09051215, and CCDC73 
cg01717164 in relation to in utero arsenic 
exposure (Koestler et al. 2013a). 
Furthermore, we evaluated the methyla-
tion of genes that were previously reported 
in candidate promoter methyla tion studies 
(Banerjee et al. 2013; Chanda et al. 2013; 
Gribble et al. 2014; Hossain et al. 2012; 
Intarasunanont et al. 2012) using a lookup 
approach in our data set for DAPK1, 
CDKN2A (P16), GMDS, C10orf32/AS3MT, 
RASSF1, PPARG, TP53, and MLH1 (see 
Supplemental Material, Table S3). Our data 
provide supporting evidence for differential 
methyla tion specifically in the promoter 
reg ions  of  CDKN2A  (cg03079681) , 
RASSF1 (cg06117233), TP53 (cg05479194, 
cg02855142, cg08119584, and cg01620719), 
and MLH1 (cg11291081 and cg05670953) in 
relation to arsenic exposure (see Supplemental 
Material, Table S3). Given the notable differ-
ences in arsenic toxicity constructs, arsenic 
exposure levels, and partici pant populations 
across published studies, future research 
is needed to further synthesize the existing 
evidence and elucidate the role of epigenetic 
mechanisms in relation to arsenic exposure 
and related diseases.
This study has several potential limitations. 
We measured DNA methyla tion in total 
Table 4. Estimated change in leukocyte cell type proportions by blood and urinary total arsenic concentrations.
Exposure CD8+ T cells CD4+ T cells NK cells B cells Monocytes Granulocytes
Blood arsenic concentration (μg/L)
0.80–2.50 Reference Reference Reference Reference Reference Reference
2.51–4.79 0.39 (–1.09, 1.87) –0.57 (–1.59, 0.44) 0.05 (–0.06, 0.15) –0.46 (–1.18, 0.26) 0.04 (–0.47, 0.55) 0.55 (–1.16, 2.26)
4.80–11.20 1.02 (–0.43, 2.47) –0.30 (–1.29, 0.70) 0.02 (–0.08, 0.12) –0.39 (–1.09, 0.32) –0.05 (–0.54, 0.45) –0.31 (–1.99, 1.37)
11.21–81.60 0.47 (–0.97, 1.90) –0.75 (–1.74, 0.24) –0.08 (–0.18, 0.02) –0.41 (–1.11, 0.29) 0.15 (–0.34, 0.64) 0.61 (–1.05, 2.28)
Urinary total arsenic concentration (μg/g)
12.0–75.0 Reference Reference Reference Reference Reference Reference
75.1–139.9 0.37 (–1.08, 1.81) –0.72 (–1.71, 0.28) –0.08 (–0.18, 0.02) –0.31 (–1.01, 0.39) 0.25 (–0.24, 0.75) 0.49 (–1.18, 2.16)
140.0–394.9 1.21 (–0.27, 2.69) –0.47 (–1.50, 0.55) –0.02 (–0.13, 0.08) –0.35 (–1.07, 0.37) 0.20 (–0.31, 0.70) –0.56 (–2.28, 1.15)
395.0–2250.0 0.99 (–0.47, 2.45) –1.18 (–2.19, –0.17)* –0.12 (–0.22, –0.01)* –0.68 (–1.39, 0.03) 0.18 (–0.32, 0.68) 0.81 (–0.88, 2.50)
*p < 0.05. 
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white blood cells, which comprise various 
leukocyte subtypes known to be associated 
with differen tial methyla tion signatures 
(Adalsteinsson et al. 2012; Reinius et al. 
2012). If arsenic exposure was associated 
with a substantial shift in leukocyte subtypes, 
then our analyses of DNA methyla tion in 
white blood cells may be confounded due to 
differences in cell type proportions. Because 
frozen unfractioned blood was used in these 
experiments, we could not evaluate the asso-
ciation between arsenic and cell type frac-
tions directly. Therefore, we utilized a novel 
statistical method to infer expected cell type 
fractions in our study samples based on a 
validated subset of methyla tion markers as a 
surrogate measure (Houseman et al. 2012); 
the assumptions of the statistical method 
have been described elsewhere (Koestler et al. 
2013a, 2013b). Based on these analyses, 
arsenic did not appear to be strongly associ-
ated with cell-type shifts, except for associa-
tions of the highest quartile of urinary total 
arsenic concentration with decreased CD4+ 
T and NK cell fractions. Therefore, we do 
not believe that the results observed in our 
analyses can be fully explained through an 
immuno toxic pathway of arsenic.
Another potential consideration for the 
findings of our study is that all participants 
had manifest arsenic skin lesions, which is 
a proxy for both chronic arsenic exposure 
and genetic susceptibility to arsenic toxicity. 
Because genotype is known to influence DNA 
methyla tion patterns (Tycko 2010), it is 
possible that the associations observed in our 
study may not be generalizable to populations 
without skin lesions. However, individuals 
with arsenical skin lesions are at increased 
risk of developing arsenic-related cancers 
and other disease conditions; therefore, the 
results of this study offer valuable insight into 
potential mechanistic pathways related to 
arsenic toxicity and carcinogenesis. Another 
potential limitation is that we did not validate 
the methyla tion signals identified with the 
Illumina platform using additional confirma-
tory methods. Because previously published 
studies have indicated very good concordance 
of the Illumina 450K platform with pyro-
sequencing data (Roessler et al. 2012), we did 
not pursue validation methods. 
The major strengths of the present study 
are the relatively large size of the study 
sample, the multiple measures of arsenic 
exposure, the broad exposure range, and the 
availability of epigenome-wide methyla tion 
data, as well as genome-wide expression and 
genetic data from the study sample. Whereas 
previous studies have demonstrated an asso-
ciation between arsenic exposure and DNA 
methyla tion, we were also able to evaluate 
potentially functional gene regulation associ-
ated with the differentially methylated loci.
Conclusions
Arsenic exposure was associated with differ-
ential gene-specific white blood cell DNA 
methyla tion at several novel loci. We also 
observed functional evidence of gene deregu-
lation that corresponded with differential 
methyla tion at a subset of these loci. The 
clinical implications of these findings in 
arsenic-exposed populations require further 
investigation.
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